Insider Selling: Questcor Pharmaceuticals Director Unloads 85,000 Shares of Stock (QCOR)
Questcor Pharmaceuticals (NASDAQ:QCOR) Director Broadwood Partners Lp sold 85,000 shares of Questcor Pharmaceuticals stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $69.10, for a total transaction of $5,873,500.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 0.13% during mid-day trading on Thursday, hitting $69.59. The stock had a trading volume of 1,677,763 shares. Questcor Pharmaceuticals has a 52-week low of $26.76 and a 52-week high of $74.76. The stock’s 50-day moving average is $59.85 and its 200-day moving average is $61.15. The company has a market cap of $4.098 billion and a price-to-earnings ratio of 15.96. Questcor Pharmaceuticals also was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 20,265,050 shares, a decline of 8.0% from the January 15th total of 22,026,789 shares. Based on an average trading volume of 2,624,401 shares, the short-interest ratio is presently 7.7 days. Currently, 34.1% of the shares of the stock are short sold.
A number of research firms have recently commented on QCOR. Analysts at Zacks reiterated a “neutral” rating on shares of Questcor Pharmaceuticals in a research note on Friday, January 24th. They now have a $68.00 price target on the stock. Separately, analysts at Mizuho reiterated a “buy” rating on shares of Questcor Pharmaceuticals in a research note on Tuesday, November 26th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $76.67.
Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.